The cytotoxic activity and selectivity of the synthesized compounds against hepatocellular carcinoma (HepG2) cellsa.
| Entry | 4a–n | HepG2 (IC50, μM) | HepG2 (IC50, μg ml−1) | VERO-B (IC50, μM) | SI* |
|---|---|---|---|---|---|
| 1 | 4a | ND | ND | ND | ND |
| 2 | 4b | 11.8 ± 2 | 5.4 | 26 | 2.2 |
| 3 | 4c | 8 ± 0.5 | 3.8 | 22 | 2.8 |
| 4 | 4d | 2 ± 0.1 | 1 | 9 | 4.5 |
| 5 | 4e | 17.3 ± 3 | 8.3 | 26 | 1.5 |
| 6 | 4f | 12 ± 1.5 | 6.3 | 30 | 2.5 |
| 7 | 4g | 20 ± 2 | 9.3 | 40 | 2 |
| 8 | 4h | 14 ± 0.22 | 6.5 | 18 | 1.3 |
| 9 | 4i | 7 ± 0.40 | 3.2 | 15 | 2.1 |
| 10 | 4j | 8 ± 1 | 4.2 | 20 | 2.5 |
| 11 | 4k | 10 ± 1.25 | 5.2 | 22 | 2.2 |
| 12 | 4l | 50 ± 3 | 22.7 | 60 | 1.2 |
| 13 | 4m | 40 ± 5 | 17.5 | 50 | 1.3 |
| 14 | 4n | 28 ± 2 | 15.7 | 40 | 1.4 |
| Positive control | Cisplatin | 5.5 ± 1.5 | 1.7 | 5 | 0.91 |
a
SI*: selectivity index, ND: not determine.